Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals launched IMCIVREE (setmelanotide) commercially in Japan for acquired hypothalamic obesity after inclusion on Japan's National Health Insurance drug price list. The launch follows August MHLW approval, the first approved therapy in Japan for acquired HO, supported by the Phase 3 TRANSCEND trial showing a statistically significant 18.8% placebo-adjusted BMI reduction.
Key figures
- Drug Name
- IMCIVREE (setmelanotide)
- Phase Of Trial
- Phase 3
- Trial enrollment
- 142
- Addressable population japan
- 5,000-8,000
- Placebo adjusted bmi reduction
- 18.8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.